Loading...
XOSLCONTX
Market cap38mUSD
Dec 20, Last price  
5.76NOK
1D
2.86%
1Q
4.73%
Jan 2017
16.36%
Name

ContextVision AB

Chart & Performance

D1W1MN
XOSL:CONTX chart
P/E
13.25
P/S
3.28
EPS
0.42
Div Yield, %
5.21%
Shrs. gr., 5y
—
Rev. gr., 5y
7.78%
Revenues
133m
+12.54%
24,644,00056,059,00051,951,00069,041,00071,091,00054,731,00053,412,00058,366,00067,115,00061,277,00064,398,00072,237,00081,917,00080,512,00090,903,00095,312,00094,746,00098,098,000117,824,000132,602,000
Net income
33m
+13.68%
-9,144,00011,671,0006,165,00020,311,00020,197,000-8,252,000-3,298,0003,578,000620,0004,880,0005,421,0005,338,0004,253,000-1,706,000-1,179,0007,398,00012,080,00034,884,00028,791,00032,729,000
CFO
45m
+72.85%
-3,87023,744193,00024,554,00021,964,000-9,557,00013,180,0007,734,0008,454,0007,663,00010,373,0009,156,0009,527,0001,948,0005,119,00025,076,00022,315,0009,473,00025,889,00044,748,000
Dividend
Nov 02, 20230.1506 NOK/sh
Earnings
Feb 02, 2025

Profile

ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; VolarView, an image enhancement software for the handheld ultrasound market segment; and GOPiCE, a technology for volumetric image enhancement in real-time. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI; and INIFY Prostate Screening for digital analysis of prostate biopsies. The company was founded in 1983 and is headquartered in Stockholm, Sweden.
URL
https://www.contextvision.com/
IPO date
Mar 06, 1997
Employees
36
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
132,602
12.54%
117,824
20.11%
98,098
3.54%
Cost of revenue
68,622
(1,269)
11,562
Unusual Expense (Income)
NOPBT
63,980
119,093
86,536
NOPBT Margin
48.25%
101.08%
88.21%
Operating Taxes
8,534
7,726
9,501
Tax Rate
13.34%
6.49%
10.98%
NOPAT
55,446
111,367
77,035
Net income
32,729
13.68%
28,791
-17.47%
34,884
188.77%
Dividends
(23,210)
Dividend yield
3.90%
Proceeds from repurchase of equity
(500)
BB yield
0.07%
Debt
Debt current
3,668
2,546
4,232
Long-term debt
6,694
6,308
13,940
Deferred revenue
Other long-term liabilities
447
1,000
Net debt
(47,489)
(31,716)
(6,745)
Cash flow
Cash from operating activities
44,748
25,889
9,473
CAPEX
(703)
(4,828)
(4,670)
Cash from investing activities
(813)
(5,300)
(4,707)
Cash from financing activities
(27,649)
(25,662)
(4,193)
FCF
45,075
78,597
109,043
Balance
Cash
57,851
40,570
24,917
Long term investments
Excess cash
51,221
34,679
20,012
Stockholders' equity
74,961
64,301
35,215
Invested Capital
32,232
28,599
25,545
ROIC
182.29%
411.37%
232.39%
ROCE
76.67%
187.77%
189.34%
EV
Common stock shares outstanding
77,368
77,368
77,368
Price
7.70
-15.75%
9.14
-44.61%
16.50
-25.34%
Market cap
595,730
-15.75%
707,139
-44.61%
1,276,564
-25.34%
EV
548,241
675,423
1,269,819
EBITDA
72,814
127,773
97,828
EV/EBITDA
7.53
5.29
12.98
Interest
214
199
98
Interest/NOPBT
0.33%
0.17%
0.11%